Rockwell Medical (RMTI) delivered an impressive performance through 2024, with its stock witnessing more than 108% year-to-date surge, outperforming the 15.5% rise of the industry and the benchmark’s 18.1% increase.The company also strongly outperformed its key rivals like EDAP TMS (EDAP) and IRIDEX (IRIX) year to date. EDAP TMS has fallen 40.3% and IRIDEX has declined 32.3% during this period.YTD Share ComparisonImage Source: Zacks Investment ResearchThis year can be regarded as a momentous period for Rock ...